iBio (NASDAQ:IBIO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

iBio (NASDAQ:IBIO) announced its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02, FiscalAI reports. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $0.03 million.

Here are the key takeaways from iBio’s conference call:

• iBio has become a clinical-stage company: its IBIO-600 myostatin/GDF11 antibody has completed single-ascending-dose testing, with the company reporting no concerning safety findings so far. Unblinded safety, half-life and possible body-composition data are expected in the first quarter of next year.
• The company highlighted non-human-primate results for its Activin E antibody, IBIO-610, saying it shifted GLP-1-associated weight loss toward fat rather than muscle; it cautioned that the study is not complete. iBio is targeting an Australian clinical-trial filing by year-end and first-in-human data in the first half of next year, with the initial study focused mainly on safety and pharmacokinetics.
• IBIO-800, a myostatin/Activin A bispecific being developed initially for PH-HFpEF, is in CMC and toxicology work, with animal efficacy results expected by the end of the second quarter next year. The company is still evaluating potential bleeding and blood-cell-production risks, so both the safety profile and clinical prospects remain uncertain.
• The amylin program remains in candidate-selection work: iBio is comparing receptor and signaling profiles and expects to choose a development candidate around mid-next year. The company said CMC and toxicology would then take another 9–12 months before the program could enter the clinic.
• Management said current cash is expected to fund operations into the second quarter of 2028 and support several planned data readouts, but also expects the company will need to raise capital sometime in the next year. That could create financing or dilution risk if partnering or other non-dilutive funding does not materialize.

iBio Stock Performance

Shares of iBio stock traded up $0.01 during midday trading on Wednesday, hitting $0.79. The company had a trading volume of 85,930 shares, compared to its average volume of 1,068,375. iBio has a 52-week low of $0.69 and a 52-week high of $3.82. The stock has a market capitalization of $51.00 million, a P/E ratio of -2.33 and a beta of 1.47. The company has a 50 day moving average of $1.01 and a 200 day moving average of $1.65.

Analyst Ratings Changes

Several brokerages have commented on IBIO. Wall Street Zen lowered shares of iBio from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. HC Wainwright initiated coverage on iBio in a report on Thursday, September 17th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $6.00.

About iBio

iBio, Inc. (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases. iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.